As EGFRmut NSCLC is uniquely sensitive to EGFR-targeting inhibitors, we hypothesized that targeting MSI2 might influence the efficacy of small molecule EGFR tyrosine kinase inhibitors in these cells. Here, MSI2 is linked to non-small cell lung carcinoma.